% \setcounter{figure}{0}
% \renewcommand{\figurename}{Extended Data Fig.}
  
% \setcounter{table}{0}
% \renewcommand{\tablename}{Extended Data Tab.}

%###########################################################
%###########################################################

% ####################################
\def\RCOL{\rowcolor{teal!40}}
%#################################### 
\begin{table}[t]   
\centering 
\captionN{PPV Achieved at 100, 112 and 150 Weeks For Each Dataset and Gender {\bf (M-CHAT/F:  sensitivity=$38.8\%$, specificity=$95\%$, PPV=$14.6\%$ between 16 and  26 months ($\approx$112 weeks))}}\label{EXT-tabssp}

  \vskip .5em

\begin{tabular}{L{.75in}|L{.75in}|L{.75in}|L{.5in}|L{.5in}|L{.75in}}
\hline
\input{../../../revision_results/roc/restricted_neg_len/RAW/ssp}
\end{tabular}
\end{table}  
%####################################
% %####################################

%#################################### 
\begin{table}[t]
\centering
\captionN{Personalized Operation Conditioned on M-CHAT/F Scores at  26 months}\label{EXT-tabboost}
  \vskip .5em

\begin{tabular} {L{.33in}|L{.33in}|L{.33in}|L{.33in}||L{.35in}|L{.35in}|L{.375in}||L{.375in}|L{.35in}|L{.35in}||L{.6in}}
\hline
\multicolumn{4}{c||}{\cellcolor{lightgray!60}M-CHAT/F Outcome}  & \multicolumn{3}{c||}{\mnp{.9in}{\vskip .2em global performance (Truven)\vskip .2em  } }&\multicolumn{3}{c||}{\mnp{1in}{\vskip .2em global performance\\(UCM)\vskip .2em }} &  \multirow{3}{*}{prevalence$^\star$}\\\cline{0-9}
 0-2  NEG & 3-7  NEG & 3-7  POS & $\geq  8$  POS & \multirow{2}{*}{\mnp{.1in}{speci-ficity}} & \multirow{2}{*}{\mnp{.1in}{sensi-tivity}} &\multirow{2}{*}{PPV}& \multirow{2}{*}{\mnp{.1in}{speci-ficity}} & \multirow{2}{*}{\mnp{.1in}{sensi-tivity}} & \multirow{2}{*}{PPV} & \\\cline{0-3}
\multicolumn{4}{c}{\cellcolor{lightgray} specificity choices}  & & & &&&&\\\hline 
  \input{../optcode_/data/boost} 
\end{tabular}
\vskip 1em

\flushleft
$^\star$Prevalence reported by CDC is $1.7\%$, while the CHOP study reports a value of $2.23\%$. The results of our optimization depend on the prevalence estimate.
\end{table}  
%####################################
%###########################################################
%###########################################################
\ifFIGS
\begin{figure*}[!t]
  \tikzexternalenable
    \tikzsetnextfilename{comorbidA}
  \vspace{-10pt}

\def\DATA{../../data_latest}
\iftikzX
 \input{Figures/figClass0_.tex}
 \else
  \includegraphics[width=0.99\textwidth]{Figures/External/comorbidA}
\fi
  \vspace{-5pt}
  
  \captionN{\textbf{Co-morbidity Patterns} Panel A and B. Difference in occurrence frequencies of diagnostic codes between true positive (TP) and true negative (TN) predictions. The dotted line on panel B shows the  abscissa lower cut-off in Panel A, illustrating the lower prevalence of codes in females. Panel C illustrates log-odds ratios for ICD9 disease categories at different ages. Importantly, the negative associations disappear when we consider older children, consistent with the lack of such reports in the literature which lack studies on very young cohorts. }\label{EXT-fig3}
  \vspace{-5pt}
  
\end{figure*}
\else
\refstepcounter{figure}\label{EXT-fig3}
\fi
% ###########################################################
% #############

%#################################### 
\begin{table}[!ht]
\centering

\mnp{.89\textwidth}{

\captionN{Boosted Sensitivity, Specificity and PPV Achieved at  \textbf{150 weeks}  Conditioned on M-CHAT/F Scores}\label{EXT-tabboost150}
  \vskip .5em

\begin{tabular} {L{.33in}|L{.33in}|L{.33in}|L{.33in}||L{.35in}|L{.35in}|L{.375in}||L{.375in}|L{.35in}|L{.35in}||L{.6in}}
\hline
\multicolumn{4}{c||}{\cellcolor{lightgray!60}M-CHAT/F Outcome}  & \multicolumn{3}{c||}{\mnp{.9in}{\vskip .2em global\\performance (Truven)\vskip .2em  } }&\multicolumn{3}{c||}{\mnp{1in}{\vskip .2em global\\performance\\(UCM)\vskip .2em }} &  \multirow{3}{*}{prevalence}\\\cline{0-9}
 0-2  NEG & 3-7  NEG & 3-7  POS & $\geq  8$  POS & \multirow{2}{*}{\mnp{.1in}{speci-ficity}} & \multirow{2}{*}{\mnp{.1in}{sensi-tivity}} &\multirow{2}{*}{PPV}& \multirow{2}{*}{\mnp{.1in}{speci-ficity}} & \multirow{2}{*}{\mnp{.1in}{sensi-tivity}} & \multirow{2}{*}{PPV} & \\\cline{0-3}
\multicolumn{4}{c}{\cellcolor{lightgray} specificity choices}  & & & &&&&\\\hline 
  \input{../optcode_/data/boost150} 
\end{tabular}}

\vspace{10pt}

\mnp{.97\textwidth}{
  \captionN{Population Stratification Results on large M-CHAT/F Study(n=20,375)  reproduced from Guthrie $\etal$~\cite{pmid31562252} }\label{EXT-tabCHOP}
    \vskip .5em

  \begin{tabular}{C{.5in} | L{1.5in}|L{1in}|L{1in}|L{1in}||L{.5in}}\hline
 \bf \sffamily   Id &  \bf \sffamily Sub-population & \bf \sffamily Test Result & \bf \sffamily ASD positive & \bf \sffamily ASD Negative & \bf \sffamily Total \% \\\hline
   A &  M-CHAT/F $\geqq 8$ & Positive & 0.34\% & 0.64\% & 0.99\% \\\hline
  B &   M-CHAT/F $\in [3,7]$ & Positive (after follow-up)& 0.52\% & 4.39\% & 4.91\% \\\hline
 C &    M-CHAT/F $\in [3,7]$ & Negative (after follow-up)& 0.14\% & 3.1\% & 3.24\% \\\hline
  D &   M-CHAT/F $\in [0,2] $ & Negative & 1.22\% & 89.63\% & 90.86\% \\\hline\hline
    Total \%& &   &2.23\% & 97.77\% & 100\% \\\hline
    \end{tabular}
}

\vspace{10pt}

\mnp{.9\textwidth}{
  \captionN{$\gamma,\gamma'$ Computed from Population Stratification Recorded In  M-CHAT/F Study~\cite{pmid31562252} ($\rho=0.0223$) }\label{EXT-tabCHOP2}
    \vskip .5em

  \begin{tabular}{C{.5in} | L{1.35in} | L{1.5in}|L{.35in}|L{.35in}|L{.35in}|L{.35in}}\hline
 \bf \sffamily   Id  &  \bf \sffamily Sub-population& \bf \sffamily Test Result & $\beta_i$ & $\rho_i$ & \bf \sffamily $\gamma_i$ & \bf \sffamily $\gamma'_i$ \\\hline
   A & M-CHAT/F $\geqq 8$ &  Positive &.0099 & .3469 &.1540  & .0066 \\\hline
  B & M-CHAT/F $\in [3,7]$ & Positive (after follow-up)& .0491 & .1059 &.2331  & .0449 \\\hline
 C &   M-CHAT/F $\in [3,7]$ & Negative (after follow-up)& .0324 & .0432 &.0627  & .0317 \\\hline
  D &  M-CHAT/F $\in [0,2] $ & Negative & .9086 & .0134 &.5471  & .9168 \\\hline
    \end{tabular}}

\end{table}
%###############################################
%###############################################
